Introduction: Crohn disease is an inflammatory bowel disease that involves any region of the alimentary tract from the mouth to the anus and it is transmural. Children with early onset are more likely to have colonic involvement. Infliximab constitutes today one of major therapeutic approaches at cases of Crohn’s disease.
Material and methods: We present the case of a 15-year-old female who was admitted in our department presenting pain of the large joints (exacerbated by movement), abdominal pain (epigastric and hypogastric), vomiting, diarrhea. In order to induce remission of the disease, we chose the step-up therapy (the only one accepted in Romania for children with Crohn disease). The initial response to immunosupressant therapy was moderate: no digestive symptoms were present, but extradigestive (articular) symptoms were still present and remission was not obtained (inflammation markers were still present and PCDAI was still above 15). We decided to try to induce remission with Infliximab.
Results: We obtained only temporary improvement of symptoms with “classical” therapy. We had a good response to Infliximab (remission was obtained), but treatment discontinuation without medical advise led to relapse after 9 months.
Conclusions: Infliximab was effective as therapy in Crohn’s disease with peripheral arthropathy, but too soon discontinuation of treatment due to patient’s non compliance determined relapse of the disease.
Tag Archives: Infliximab
Acute Infusion Reaction to Infliximab in a Case of Crohn’s Disease with Recto-Scrotal Fistula
Crohn disease is an inflammatory bowel disease that involves any region of the alimentary tract from the mouth to the anus and it is transmural. Children with early onset are more likely to have colonic involvement. Infliximab constitutes today one of major therapeutic approaches in severe and fistulising cases of Crohn disease. We present the case of a 16 year-old boy who was admitted to our department presenting recto-scrotal fistula, fever, tenesmus, red-bloody stools, pain during and after defecation. In order to induce remission of the disease, we administrated Infliximab. The initial response to therapy was good, but he developed an acute infusion reaction during the administration of the 3rd dose, which forced us to quit this therapy.